Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis

Zheng,Shu-Rong; Guo,Gui-Long; Zhang,Wei; Huang,Guan-Li; Hu,Xiao-Qu; Zhu,Jin; Huang,Qi-Di; You,Jie; Zhang,Xiao-Hua

doi:10.3892/or.2012.1634

Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis

Authors:
- Shu-Rong Zheng
- Gui-Long Guo
- Wei Zhang
- Guan-Li Huang
- Xiao-Qu Hu
- Jin Zhu
- Qi-Di Huang
- Jie You
- Xiao-Hua Zhang
View Affiliations

Affiliations: Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, Zhejiang 325000, P.R. China, Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, No.2, Fu Xue Road, Wenzhou, Zhejiang 325000, P.R. China
Published online on: January 12, 2012 https://doi.org/10.3892/or.2012.1634
Pages: 1149-1155

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Accumulating evidence shows that mircroRNAs (miRNAs) play a vital role in tumorigenesis. miR-155 is one of the most multifunctional miRNAs whose overexpression has been found to be associated with different types of cancer including breast cancer. To further determine the potential involvement of miR-155 in breast cancer, we evaluated the expression levels of miR-155 by real-time PCR and correlated the results with clinicopathological features. Matched non-tumor and tumor tissues of 42 infiltrating ductal carcinomas and 3 infiltrating lobular carcinomas were analyzed for miR-155 expression by real-time PCR. Further, we used an antisense technique to inhibit miR-155 expression in vitro. WST-8 test was performed to evaluate cell viability and apoptosis assay was used to investigate the effect of the miR-155 antisense oligonucleotide (miR-155 ASO) on HS578T cell death. The expression levels of miR-155 were significantly higher in tumor tissues than the levels in matched non-tumor tissues (P<0.001). Up-regulated miR-155 expression was associated with lymph node positivity (P=0.034), higher proliferation index (Ki-67 >10%) (P=0.019) and advanced breast cancer TNM clinical stage (P=0.002). Interestingly, we next found that miR-155 expression levels had close relations with ER status (P=0.041) and PR status (P=0.029). Transfection efficiency detected by flow cytometry was higher than 70%, the WST-8 test showed that viability of HS578T cells was greatly reduced after transfection with miR-155 ASO compared with the scramble (SCR) group or the liposome group. The Annexin V-FITC/PI assay also indicated that transfection with miR-155 ASO promoted apoptosis.

View Figures

View References

1	Ambros V: MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 113:673–676. 2003. View Article : Google Scholar : PubMed/NCBI
2	Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
3	Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A and Enright AJ: miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res. 34:D140–D144. 2006. View Article : Google Scholar : PubMed/NCBI
4	He L, Thomson JM, Hemann MT, et al: A microRNA polycistron as a potential human oncogene. Nature. 435:828–833. 2005. View Article : Google Scholar : PubMed/NCBI
5	Tam W and Dahlberg JE: miR-155/BIC as an oncogenic microRNA. Genes Chromosomes Cancer. 45:211–212. 2006. View Article : Google Scholar : PubMed/NCBI
6	Papagiannakopoulos T, Shapiro A and Kosik KS: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res. 68:8164–8172. 2008. View Article : Google Scholar : PubMed/NCBI
7	Hammond SM: MicroRNAs as tumor suppressors. Nat Genet. 39:582–583. 2007. View Article : Google Scholar : PubMed/NCBI
8	Tazawa H, Tsuchiya N, Izumiya M and Nakagama H: Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA. 104:15472–15477. 2007. View Article : Google Scholar : PubMed/NCBI
9	Yanaihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
10	Mattie MD, Benz CC, Bowers J, et al: Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 5:242006. View Article : Google Scholar
11	Chen Y and Stallings RL: Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 67:976–983. 2007. View Article : Google Scholar : PubMed/NCBI
12	Ru Y, Dancik GM and Theodorescu D: Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Curr Opin Urol. 21:420–427. 2011. View Article : Google Scholar : PubMed/NCBI
13	Eis PS, Tam W, Sun L, et al: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA. 102:3627–3632. 2005. View Article : Google Scholar : PubMed/NCBI
14	Wald AI, Hoskins EE, Wells SI, Ferris RL and Khan SA: Alteration of microRNA profiles in squamous cell carcinoma of the head and neck cell lines by human papillomavirus. Head Neck. 33:504–512. 2011. View Article : Google Scholar : PubMed/NCBI
15	Kong W, He L, Coppola M, Guo J, Esposito NN, Coppola D and Cheng JQ: MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem. 285:17869–17879. 2010. View Article : Google Scholar : PubMed/NCBI
16	Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006. View Article : Google Scholar : PubMed/NCBI
17	Juan D, Alexe G, Antes T, et al: Identification of a microRNA panel for clear-cell kidney cancer. Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
18	Du ZM, Hu LF, Wang HY, Yan LX, Zeng YX, Shao JY and Ernberg I: Upregulation of MiR-155 in nasopharyngeal carcinoma is partly driven by LMP1 and LMP2A and downregulates a negative prognostic marker JMJD1A. PLoS One. 6:e191372011. View Article : Google Scholar : PubMed/NCBI
19	Bundred NJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 27:137–142. 2001. View Article : Google Scholar : PubMed/NCBI
20	Devi KR, Kuruvila S and Musa MM: Pathological prognostic factors in breast carcinoma. Saudi Med J. 21:372–375. 2000.PubMed/NCBI
21	Wiseman SM, Makretsov N, Nielsen TO, et al: Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 103:1770–1777. 2005. View Article : Google Scholar
22	Singletary SE, Allred C, Ashley P, et al: Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg Clin North Am. 83:803–819. 2003. View Article : Google Scholar : PubMed/NCBI
23	Zhang RG, Zhang RP, Wang XW and Xie H: Effects of cisplatin on telomerase activity and telomere length in BEL-7404 humanhepatoma cells. Cell Res. 12:55–62. 2002. View Article : Google Scholar : PubMed/NCBI
24	O’Connell RM, Taganov KD and Boldin MP: MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci USA. 104:1604–1609. 2007.PubMed/NCBI
25	O’Connell RM, Kahn D, Gibson WS, et al: MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity. 33:607–619. 2010.
26	Bhattacharyya S, Balakathiresan NS, Dalgard C, et al: Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem. 286:11604–11615. 2011. View Article : Google Scholar : PubMed/NCBI
27	O’Connell RM, Rao DS, Chaudhuri AA, et al: Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 205:585–594. 2008.PubMed/NCBI
28	Urbich C, Kuehbacher A and Dimmeler S: Role of microRNAs in vascular diseases, inflammation, and angiogenesis. Cardiovasc Res. 79:581–588. 2008. View Article : Google Scholar : PubMed/NCBI
29	Jiang S, Zhang HW, Lu MH, et al: MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 70:3119–3127. 2010. View Article : Google Scholar : PubMed/NCBI
30	Pedersen IM, Otero D, Kao E, Miletic AV, et al: Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of B cell lymphomas. EMBO Mol Med. 1:288–295. 2009. View Article : Google Scholar : PubMed/NCBI
31	Tili E, Croce CM and Michaille JJ: miR-155: on the crosstalk between inflammation and cancer. Int Rev Immunol. 28:264–284. 2009. View Article : Google Scholar : PubMed/NCBI
32	Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wrba F, Reiner A, Markis-Ritzinger E, Holzner JH, Reiner G and Spona J: Prognostic significance of immunohistochemical parameters in breast carcinomas. Pathol Res Pract. 183:277–283. 1988. View Article : Google Scholar : PubMed/NCBI
34	Carter CL, Allen C and Henson DE: Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 63:181–187. 1989. View Article : Google Scholar : PubMed/NCBI
35	De Azambuja E, Cardoso F, de Castro G Jr, et al: Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 96:1504–1513. 2007.PubMed/NCBI
36	Zhu W, Qin W, Atasoy U and Sauter ER: Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2:892009. View Article : Google Scholar : PubMed/NCBI
37	Lu J and Tsourkas A: Imaging individual microRNAs in single mammalian cells in situ. Nucleic Acids Res. 37:e1002009. View Article : Google Scholar : PubMed/NCBI
38	Lee YT and Markland FS: Steroid receptors study in breast carcinoma. Med Pediatr Oncol. 5:153–166. 1978. View Article : Google Scholar : PubMed/NCBI
39	Paone JF, Abeloff MD, Ettinger DS, Arnold EA and Baker RR: The correlation of estrogen and progesterone receptor levels with response to chemotherapy for advanced carcinoma of the breast. Surg Gynecol Obstet. 152:70–74. 1981.PubMed/NCBI
40	Clark GM and McGuire WL: Prognostic factors in primary breast cancer. Breast Cancer Res Treat. 3(Suppl): S69–S72. 1983. View Article : Google Scholar
41	Linnstaedt SD, Gottwein E, Skalsky RL, Luftig MA and Cullen BR: Virally induced cellular microRNA miR-155 plays a key role in B-cell immortalization by Epstein-Barr virus. J Virol. 84:11670–11678. 2010. View Article : Google Scholar : PubMed/NCBI
42	Qin A, Zhou Y, Sheng M, Fei G, Ren T and Xu L: Effects of microRNA-155 on the growth of human lung cancer cell line 95D in vitro. Zhongguo Fei Ai Za Zhi. 14:575–580. 2011.PubMed/NCBI